What's Happening?
Neuromod Devices, an Irish medical technology company, is expanding the availability of its tinnitus treatment device, Lenire, to Canada and Australia in 2026. Lenire, which uses bimodal neuromodulation, has been proven effective in clinical trials and received
De Novo approval from the US FDA in 2023. The expansion will create 25 new jobs across engineering, operations, and sales. Lenire will be available in 17 hearing clinics in Canada starting March 2026, with plans to enter the Australian market in Q4 2026. The company also plans to expand its presence in Europe.
Why It's Important?
The expansion of Lenire's availability addresses the needs of millions suffering from tinnitus, a condition affecting 15% of the global adult population. By providing a proven treatment option, Neuromod Devices is enhancing access to care for those with this often-underserved condition. The creation of new jobs in the medical technology sector also contributes to economic growth and innovation. The expansion reflects the growing demand for effective tinnitus treatments and the potential for further advancements in neuromodulation technology.
